Abbott Laboratories ABT
At closeNov 5, 2026, 7:45 PM EST
After hours · Nov 5, 7:45 PM ET
- YTD
- -9.33%
- 1 year
- -8.78%
- Market cap
- 196.57B
- Revenue (ttm)
- 48.23B
- Profit margin
- 9.75%
- EPS (ttm)
- 2.69
- Shares out
- 1.74B
- P/E ratio
- 42.23
- Forward P/E
- 19.10
- Dividend
- 2.52 (2.30%)
- Ex-dividend date
- Oct 14, 2026
- YTD return
- -9.33%
- 1-year return
- -8.78%
- Volume
- 10.29M
- Avg volume
- 8.81M
- Open
- 117.00
- Previous close
- 115.51
- Day's range
- 112.66 – 117.07
- 52-week range
- 81.97 – 132.03
- Beta
- 0.54
- Analysts
- Buy
- Price target
- 118.52 (+4.3%)
- Earnings date
- Jan 28, 2027
5D +7.14 (+6.71%)
Key statistics
- Enterprise value
- 227.65B
- PEG ratio
- 1.56
- Price / sales
- 4.09
- Price / book
- 3.84
- Dividend yield
- 2.18%
- Payout ratio
- 92.54%
- Revenue growth
- 14.50%
- Free cash flow
- 0
- Total cash
- 5.60B
- Total debt
- 32.72B
- Return on equity
- 0.00%
- Short % of float
- 1.12%
- 50-day average
- 104.05
- 200-day average
- 101.54
Analyst view
Consensus: buy
- Target (low)
- 100.00
- Target (mean)
- 118.52
- Target (high)
- 130.00
- Strong buy5
- Buy18
- Hold5
- Sell0
- Strong sell0
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 1.64.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 1.64 | — | — | — |
| Oct 21, 2026 | Sep 30, 2026 | 1.42 | 1.42 | 0.00 | 0.00% |
| Jul 16, 2026 | Jun 30, 2026 | 1.28 | 1.31 | +0.03 | +2.34% |
| Apr 16, 2026 | Mar 31, 2026 | 1.14 | 1.15 | +0.01 | +0.88% |
| Jan 22, 2026 | Dec 31, 2025 | 1.50 | 1.50 | 0.00 | 0.00% |
| Oct 15, 2025 | Sep 30, 2025 | 1.30 | 1.30 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Argus Research | down | Buy | Hold |
| Oct 23, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 22, 2026 | Citigroup | main | Buy | Buy |
| Oct 22, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 22, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 22, 2026 | JP Morgan | main | Overweight | Overweight |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- abbott.com
News
These 12 stocks are good bets to beat the 10-year Treasury over the next decade 
99,391 Shares of Abbott Laboratories $ABT Bought by Associated Banc Corp 
Abbott Laboratories $ABT Stock: Heritage Investors Management Corp Trims Holdings 
Abbott Touts Favorable Outcomes In Cardiovascular Device Trials 
Abbott Touts Favorable Outcomes In Cardiovascular Device Trials 
Abbott Announces One-Year Results For Its Amulet 360 Left Atrial Appendage Occluder From The VERITAS Study; Data Show Meaningful Closure Rates Of Left Atrial Appendage And A Low Incidence Of Stroke In People With Atrial Fibrillation Not Caused By A Heart Valve Issue 
Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke 
2 Safe S&P 500 Healthcare Dividend Stocks Boomers Can Buy and Hold Forever - Reported Sunday, Abbott’s TECTONIC Trial Of Investigational SonicForce Coronary IVL System Meets Primary Safety And Effectiveness Endpoints, With 0.3% 30-Day Target Lesion Failure And 97% Procedural Success In 335 Patient
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
Your note
Sign in to keep a note on ABT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALLEN HUBERT L. | Officer | Stock Award(Grant) | Feb 24, 2025 | 200,281 |
| BOUDREAU PHILIP P | Chief Financial Officer | Purchase | Apr 22, 2026 | 0 |
| CONROY KEVIN T | Director | Stock Award(Grant) | Apr 23, 2026 | 133,737 |
| EARNHARDT LISA D | Officer | Stock Award(Grant) | Feb 23, 2026 | 98,984 |
| FORD ROBERT B. | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 24, 2026 | 522,664 |
| MORELAND MARY K | Officer | Sale | Mar 1, 2026 | 116,136 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.82% | 152,563,476 | 17.30B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.57% | 113,750,994 | 12.90B | Jun 29, 2026 |
| State Street Corporation | 4.68% | 80,926,234 | 9.18B | Jun 29, 2026 |
| Charles Schwab Investment Management, Inc. | 3.45% | 59,674,507 | 6.77B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.83% | 49,017,866 | 5.56B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.27% | 39,219,337 | 4.45B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.20% | 55,297,279 | 6.27B | Jun 29, 2026 |
| SCHWAB STRATEGIC TRUST-Schwab US Dividend Equity ETF | 2.75% | 47,631,745 | 5.40B | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.61% | 45,138,490 | 5.12B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 23,056,907 | 2.61B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 22,487,991 | 2.55B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 21,408,918 | 2.43B | Sep 29, 2026 |